{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"26070502141d14fcad32a5f707ff56589e5f00c31618ea157dfcc30de13fcdb8","attributes":{"feedName":"fda","feedSource":"fda","title":"Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry","description":"Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity found in Mylanâ€™s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and certain industrial processes.","link":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-issues-voluntary-nationwide-recall-all-amlodipinevalsartan-combination-0","publicationDate":"2018-11-27T20:13:00.000Z","state":"sent","affected":[],"allergens":[],"audience":["consumers"],"categories":["drugs"],"contaminants":["foreign"],"distribution":["AL","AK","AZ","AR","CA","CO","CT","DE","DC","FL","GA","HI","ID","IL","IN","IA","KS","KY","LA","ME","MD","MA","MI","MN","MS","MO","MT","NE","NV","NH","NJ","NM","NY","NC","ND","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VT","VA","WA","WV","WI","WY"],"risk":"possible","token":"5d9e689f8b079e002a25104b"}}}